Participating Faculty

Supplements and Featured Publications, Managed Care Pharmacy and the Evolving Diabetes Treatment Paradigm - Are We Capable of Disease Contr, Volume 16, Issue 7 Suppl

Managed Care Pharmacy and the Evolving Diabetes Treatment Paradigm-Are We Capable of Disease Control?

This supplement to The American Journal of Managed Care reviews the efficacy and safety of incretin-based therapies in type 2 diabetes, discusses barriers to effective management of this disease, and describes strategies and interventions that can be implemented by managed care to ensure optimal outcomes.

Faculty

Jeffrey D. Dunn, PharmD, MBA

Formulary and Contract Manager

SelectHealth, Inc.

Alan J. Garber, MD, PhD, FACE

Professor of Medicine, Biochemistry and Molecular Biology,

and Molecular & Cellular Biology

Division of Diabetes, Endocrinology, & Metabolism

Baylor College of Medicine

Curtis Triplitt, PharmD, CDE

Clinical Assistant Professor of Medicine

Texas Diabetes Institute

Clinical Assistant Professor of Pharmacy

University of Texas Health Science Center at San Antonio

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a posi­tion to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommenda­tions. PIM is committed to providing its learners with high-quality CME activi­ties and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest or a commercial interest.

Faculty Disclosures

Within the past 12 months, the faculty reported the following financial relation­ships or relationships to products or devices they or their spouse/life partner have had with commercial interests related to the content of this CME activity:

Jeffrey D. Dunn, PharmD, MBA

Consultant/advisory boards: AstraZeneca, Takeda, United BioSource

Receipt of payment for involvement in the preparation of this manuscript: Novo Nordisk

Alan J. Garber, MD, PhD, FACE

Consultant/advisory boards/grants/honoraria/lecturer/meeting or conference attendance: Merck, Novo Nordisk

Expert testimony/receipt of payment for involvement in the preparation of this manuscript: Novo Nordisk

Curtis Triplitt, PharmD, CDE

Lecturer/receipt of payment for involvement in the preparation of this manuscript: Novo Nordisk

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have had with commercial interests related to the content of this CME activity:

Steve Casebeer, MBA; Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Patricia Staples, MSN, NP-C, CCR-N; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD

; and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner have not had any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The American Journal of Managed Care has no relevant financial relationships to disclose.